Company research
Evofem Biosciences, Inc.
CIK 1618835Updated Sep 24, 2026
SecurityEVFM · OTC · equity
Name history
Neothetics, Inc. · through Jan 5, 2018
EVFM price & chart
Loading TradingView…
OTC:EVFM on TradingView ↗In the news
No coverage from other publishers is available.
Recent filings
Entry into a Material Definitive Agreement
Items 1.01, 9.01
10-Q filing
SCHEDULE 13D filing
Regulation FD Disclosure
Items 7.01, 9.01
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 1.01, 2.03, 9.01
Show 5 more recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Items 1.01, 7.01, 9.01
Entry into a Material Definitive Agreement
Items 1.01, 9.01
Termination of a Material Definitive Agreement
Items 1.02, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 20,274,000Source | 23,789,000Source | 10,554,000Source | 25,163,000Source |
| Property, Plant and Equipment, NetUSD | 418,000Source | 458,000Source | 1,203,000Source | 3,940,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 578,000Source | — | — | 2,769,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 12,480,000Source | 9,832,000Source | 5,738,000Source | 1,126,000Source |
| Inventory, NetUSD | 1,129,000Source | 1,577,000Source | 1,697,000Source | 5,379,000Source |
| Assets, CurrentUSD | 15,284,000Source | 13,609,000Source | 9,210,000Source | 12,699,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,097,000Source | 1,459,000Source | 1,195,000Source | 2,218,000Source |
| Operating Lease, Right-of-Use AssetUSD | 182,000Source | 89,000Source | 106,000Source | 4,406,000Source |
| Other Assets, NoncurrentUSD | 42,000Source | 36,000Source | 35,000Source | 4,118,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 89,711,000Source | 90,264,000Source | 72,471,000Source | 96,963,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | — | — | 0Source |
| Common Stock, Value, IssuedUSD | 13,000Source | 11,000Source | 2,000Source | 12,000Source |
| Additional Paid in CapitalUSD | 831,859,000Source | 829,026,000Source | 823,036,000Source | — |
| Retained Earnings (Accumulated Deficit)USD | -897,390,000Source | -897,664,000Source | -888,699,000Source | -938,694,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -8,818,000Source | -2,630,000Source | -849,000Source | 49,527,000Source |
| Stockholders' Equity Attributable to ParentUSD | -74,336,000Source | -71,257,000Source | -66,510,000Source | -71,800,000Source |
| Additional Paid in Capital, Common StockUSD | — | — | — | 817,355,000Source |
| Liabilities and EquityUSD | 20,274,000Source | 23,789,000Source | 10,554,000Source | 25,163,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 84,820,000Source | 80,448,000Source | 72,463,000Source | 93,830,000Source |
| Operating Lease, Liability, CurrentUSD | 128,000Source | 82,000Source | 97,000Source | 2,311,000Source |
| Accounts Payable, CurrentUSD | 13,153,000Source | 16,172,000Source | 17,020,000Source | 14,984,000Source |
| Operating Lease, Liability, NoncurrentUSD | 54,000Source | 7,000Source | 8,000Source | 3,133,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 1,292,000Source | 5,509,000Source | 4,227,000Source | 4,124,000Source |
| Deferred Revenue, CurrentUSD | 402,000Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 166,000Source | 847,000Source | 1,189,000Source | 3,313,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 2,648,000Source | 4,094,000Source | 4,612,000Source | -5,323,000Source |
| Increase (Decrease) in InventoriesUSD | 260,000Source | -57,000Source | -2,106,000Source | -1,566,000Source |
| Increase (Decrease) in Accounts PayableUSD | 182,000Source | -910,000Source | 4,090,000Source | 4,474,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -1,992,000Source | -3,885,000Source | -8,968,000Source | -70,410,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | 555,000Source | — | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -62,000Source | -569,000Source | -4,000Source | -341,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 5,000Source | 14,000Source | 4,000Source | 341,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | 0Source |
| Payments for Repurchase of Common StockUSD | — | — | — | 18,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 1,891,000Source | 4,615,000Source | 4,776,000Source | 61,939,000Source |
| Repayments of Long-term DebtUSD | — | — | 1,154,000Source | 5,892,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -163,000Source | 161,000Source | -4,196,000Source | -8,812,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 578,000Source | 741,000Source | 580,000Source | 4,776,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 16,000Source | 159,000Source | 338,000Source | 698,000Source |
| Income Taxes Paid, NetUSD | 2,000Source | 8,000Source | 4,000Source | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 166,000Source | 847,000Source | 1,189,000Source | 3,313,000Source |
| Amortization of Debt Issuance CostsUSD | — | 28,000Source | 224,000Source | — |
| Amortization of Intangible AssetsUSD | 499,000Source | 619,000Source | — | — |
| DepreciationUSD | 19,000Source | 30,000Source | — | — |
| Fair Value, Option, Changes in Fair Value, Gain (Loss)USD | — | — | — | 82,465,000Source |
| Gain (Loss) on Sale of DerivativesUSD | — | -3,300,000Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -20,000Source | -734,000Source | -2,511,000Source | -926,000Source |
| Gain (Loss) on Termination of LeaseUSD | — | — | 466,000Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | 977,000Source | 75,337,000Source | — |
| General and Administrative ExpenseUSD | 7,393,000Source | 11,565,000Source | 14,950,000Source | 27,563,000Source |
| Income Tax Expense (Benefit)USD | 2,000Source | — | 17,000Source | 44,000Source |
| Inventory Write-downUSD | 700,000Source | 63,000Source | 1,576,000Source | -300,000Source |
| Investment Income, InterestUSD | 15,000Source | 16,000Source | 31,000Source | 85,000Source |
| Net Income (Loss) Attributable to ParentUSD | 391,000Source | -8,860,000Source | 52,979,000Source | -76,698,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 274,000Source | -8,965,000Source | 49,995,000Source | -78,014,000Source |
| Nonoperating Income (Expense)USD | -2,979,000Source | -1,184,000Source | 70,843,000Source | 7,470,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | -2,087,000Source |
| Payments of Financing CostsUSD | — | — | — | 1,202,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | 5,640,000Source | 11,500,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | 0Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 20,183,000Source | 19,363,000Source | 18,218,000Source | 16,837,000Source |
| Cost of RevenueUSD | 4,617,000Source | 3,834,000Source | 6,512,000Source | 4,415,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Operating Income (Loss)USD | 3,372,000Source | -7,676,000Source | -17,847,000Source | -84,124,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | -2,087,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 393,000Source | -8,860,000Source | 52,996,000Source | -76,654,000Source |
| Income Tax Expense (Benefit)USD | 2,000Source | — | 17,000Source | 44,000Source |
| Net Income (Loss) Attributable to ParentUSD | 391,000Source | -8,860,000Source | 52,979,000Source | -76,698,000Source |
| Earnings Per Share, BasicUSD per share | 0Source | -0.12Source | 10.36Source | -1.34Source |
| Earnings Per Share, DilutedUSD per share | 0Source | -0.12Source | 0.05Source | -1.34Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 123,657,915Source | 75,195,615Source | 4,826,763Source | 58,248,079Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 6,421,746,555Source | 75,195,615Source | 984,038,574Source | 58,248,079Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 499,000Source | 619,000Source | — | — |
| Costs and ExpensesUSD | 16,811,000Source | 27,039,000Source | 36,065,000Source | 100,961,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | -17,000Source | 44,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 477,000Source | 1,015,000Source |
| Fair Value, Option, Changes in Fair Value, Gain (Loss)USD | — | — | — | 82,465,000Source |
| General and Administrative ExpenseUSD | 7,393,000Source | 11,565,000Source | 14,950,000Source | 27,563,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 393,000Source | -8,860,000Source | 52,996,000Source | -76,654,000Source |
| Interest ExpenseUSD | 2,366,000Source | 2,243,000Source | 2,270,000Source | 2,176,000Source |
| Interest Expense, DebtUSD | 2,366,000Source | 2,231,000Source | 2,270,000Source | — |
| Interest Revenue (Expense), NetUSD | 1,000,000Source | — | — | — |
| Investment Income, InterestUSD | 15,000Source | 16,000Source | 31,000Source | 85,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 274,000Source | -8,965,000Source | 49,995,000Source | -78,014,000Source |
| Nonoperating Income (Expense)USD | -2,979,000Source | -1,184,000Source | 70,843,000Source | 7,470,000Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | 117,000Source | — | — | — |
| Research and Development ExpenseUSD | — | 1,845,000Source | 2,939,000Source | 25,032,000Source |
| Selling and Marketing ExpenseUSD | 9,682,000Source | 9,176,000Source | 11,664,000Source | 43,951,000Source |
Filing attachments
ex99-1.htm · 8-K · 2026-09-23
Exhibit 99.1 Evofem Biosciences Adds Additional Manufacturing Capacity for PHEXX® to Support Global Growth Strategy - Additional manufacturing source expected to improve supply chain flexibility and reduce unit costs by 40% or more following regulatory approval - SAN DIEGO, CA, September 23, 2026 - Women’s health innovator Evofem Biosciences, Inc. (OTCID: EVFM) has achieved an important milestone in its strategy to support long-term growth, enhance manufacturing flexibility, and reduce cost…
Read attachment ↗ex99-1.htm · 8-K · 2026-05-18
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Evofem Reports First Quarter 2026 Financial Results and Provides Business Update - Advancing Strategy to Increase and Diversify Revenue through Ex-U.S. Commercialization - SAN DIEGO, CA, May 18, 2026 - Women’s health innovator Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the first quarter ended March 31, 2026. “Evofem continues to execute our strategy to increase revenues and to diversify a…
Read attachment ↗ex99-1.htm · 8-K · 2026-04-30
EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 Evofem Announces Exclusive Agreement for the Distribution and Commercialization of SOLOSEC in Sub-Saharan Africa - SOLOSEC® (secnidazole) 2g Oral Granules is an FDA-Approved Single-Dose Oral Treatment for Bacterial Vaginosis and Trichomoniasis - SAN DIEGO, CA, April 27, 2026 - Women’s health innovator Evofem Biosciences, Inc. (OTCID: EVFM) (Evofem or the Company) today announced that it has entered into an exclusive Distribution Agreement with C…
Read attachment ↗